Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUQ: Neoadjuvant and Maintenance Anti-PD1 for Resectable Mucosal Melanoma
2024-513027-16-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab and lenvatinib in mucosal melanoma (MM) (2 cohorts), sponsored by Gustave Roussy. Primary endpoint: Disease-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
pembrolizumablenvatinib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on 2024-513027-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513027-16-00.